NASDAQ: SGENSeagen Inc Stock
$213.21-0.31 (-0.15%)
Updated Nov 30, 2023
SGEN Price
$213.21
Fair Value Price
N/A
Market Cap
$40.22B
52 Week Low
$116.08
52 Week High
$217.51
P/E
-53.3x
P/B
15.77x
P/S
17.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.30B
Earnings
-$750.23M
Gross Margin
75.4%
Operating Margin
-32.12%
Profit Margin
-32.6%
Debt to Equity
0.43
Operating Cash Flow
-$540M
Beta
0.7
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SGEN Overview
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SGEN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SGEN is poor value based on its book value relative to its share price (15.77x), compared to the US Biotechnology industry average (5.4x)
P/B vs Industry Valuation
SGEN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SGEN due diligence checks available for Premium users.
Be the first to know about important SGEN news, forecast changes, insider trades & much more!
SGEN News
Valuation
SGEN fair value
Fair Value of SGEN stock based on Discounted Cash Flow (DCF)
Price
$213.21
Fair Value
$216.80
Undervalued by
1.65%
SGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SGEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-53.3x
Industry
12.22x
Market
29.24x
SGEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
15.77x
Industry
5.4x
SGEN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SGEN's financial health
Profit margin
Revenue
$648.7M
Net Income
-$215.8M
Profit Margin
-33.3%
SGEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SGEN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.6B
Liabilities
$1.1B
Debt to equity
0.43
SGEN's short-term assets ($2.55B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SGEN's short-term assets ($2.55B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SGEN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$35.8M
Investing
$142.5M
Financing
$15.5M
SGEN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SGEN vs Biotech Stocks
Seagen Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.